CDK4 and breast cancer: In turn, antiestrogens (e.g., tamoxifen and fulvestrant) and selective inhibitors of CDK4/6 (e.g., Palbociclib) counteract E2 activity, triggering cell cycle arrest in G1 phase of the cell cycle in BC cells [12,31].